Figure 1: Top industry sponsors for clinical trials in Israel, 2012-2016. Source: GlobalData, Pharma Intelligence Center, Deal Analytics [Accessed 31 May 2017]
Go deeper with GlobalData
With regard to the distribution of clinical trials according to therapy areas in Israel, oncology was the most frequent with 1,162 clinical trials, followed by central nervous system with 332 clinical trials, cardiovascular with 299, metabolic disorders with 207, and infectious diseases with 204, as shown in Figure 1.
Gastrointestinal, immunology, hematological disorders, respiratory and ophthalmology were the remaining therapy areas that contributed to the list of the ten therapy areas that featured the most commonly in clinical trials in Israel. In all of the five major therapy areas, and particularly in oncology, industry-sponsored clinical trials were more numerous than those sponsored by academic and government institutions.
Figure 2: Clinical trials in Israel for the top five indications by phase, 2012–2016. Source: GlobalData, Pharma Intelligence Center, Deal Analytics [Accessed 31 May 2017]
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAmong all the indications for clinical trials in this dataset, the largest number of trials was carried out for type 2 diabetes, followed by non-small cell lung cancer, breast cancer, ulcerative colitis, and rheumatoid arthritis. For the five major indications, Phase III trials were predominant. Type 2 diabetes was the indication with the most Phase III trials and the least number of Phase II trials as compared to the other top five indications, as seen in Figure 2.
Furthermore, GlobalData analysed the distribution of clinical trials with industry sponsorship versus non-industry sponsored trials combined for the five major indications in Israel between 2012 and 2016. For all five indications, industry sponsors were more prominent than non-industry sponsors; there were 17.5 times more industry-sponsored trials than non-industry sponsored trials for rheumatoid arthritis, which was the highest ratio compared to all other indications (as shown in Figure 3).
Figure 3: Clinical trials in Israel for the top five indications by sponsor type , 2012-2016. Source: GlobalData, Pharma Intelligence Center, Deal Analytics [Accessed 31 May 2017]
Click here to access GlobalData’s whitepaper, ‘Clinical Trials Landscape in Israel, 2012-2016’
